相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
John J. P. Kastelein et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia
Joep C. Defesche et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia
G. Kees Hovingh et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
Donald M. Lloyd-Jones et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors
Marcello Arca
ATHEROSCLEROSIS (2017)
Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia
Manuela Casula et al.
ATHEROSCLEROSIS (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Alberico L. Catapano et al.
ATHEROSCLEROSIS (2016)
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
Henry N. Ginsberg et al.
CARDIOVASCULAR DRUGS AND THERAPY (2016)
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1-Full Report
Terry A. Jacobson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)